Omega PF™
Gastroesophageal Reflux Disease (GERD)
Key Facts
About Aplos Medical
Aplos Medical is a clinical-stage medical device company pioneering a novel, minimally invasive implant for gastroesophageal reflux disease (GERD). Its lead product, the Omega PF™, is a small, Ω-shaped device designed to be implanted laparoscopically to prevent acid reflux while aiming to minimize common side effects like dysphagia. The company has achieved key regulatory milestones, including FDA Investigational Device Exemption (IDE) approval and patents in major markets, and is actively seeking investment partners to fund its ongoing clinical studies. With a veteran management team boasting experience in bringing over 200 products to market, Aplos is positioning its technology as a 'turning point' in the multi-billion dollar GERD treatment landscape.
View full company profileTherapeutic Areas
Other Gastroesophageal Reflux Disease (GERD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Anti-Reflux Band Mucosectomy (ARBM) | Endolastic | Pre-clinical |
| Tegoprazan | Sebela Pharmaceuticals | NDA Submitted |